(PCVX) Vaxcyte - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92243G1085
PCVX: Vaccines, Proteins, Antibiotics, Bacteria, Diseases, Prevention
Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage biotechnology company, is at the forefront of developing innovative protein vaccines to combat bacterial infectious diseases. Their approach focuses on precision and efficiency, leveraging cutting-edge science to address significant public health challenges.
Their lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine, designed to offer broader protection against invasive pneumococcal disease compared to existing vaccines. This could potentially capture a substantial share of the multi-billion-dollar pneumococcal vaccine market.
Antibiotic resistance is a growing global concern, and Vaxcyte is tackling this head-on with VAX-31, aimed at emerging strains, and VAX-A1, targeting Group A Streptococcus, a major cause of infections. These efforts position the company to address unmet needs in infectious disease prevention.
Beyond respiratory infections, Vaxcyte is exploring other high-impact areas. VAX-PG targets periodontitis, a condition affecting millions, and VAX-GI aims to prevent Shigella, a significant cause of diarrhea globally. This diversified pipeline underscores the companys commitment to broad public health impact.
Since renaming from SutroVax in 2020, Vaxcyte has established itself in San Carlos, California. Their market cap of ~$1.1 billion reflects investor confidence in their pipeline and technology. With a price-to-book ratio of 3.25, they are well-positioned for future growth and partnerships in the biotech and pharmaceutical industries.
Additional Sources for PCVX Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
PCVX Stock Overview
Market Cap in USD | 9,576m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2020-06-12 |
PCVX Stock Ratings
Growth 5y | 38.7% |
Fundamental | -54.6% |
Dividend | 0.0% |
Rel. Strength | -34.6 |
Analysts | 4.82/5 |
Fair Price Momentum | 30.23 USD |
Fair Price DCF | - |
PCVX Dividends
No Dividends PaidPCVX Growth Ratios
Growth Correlation 3m | -75.2% |
Growth Correlation 12m | 40.9% |
Growth Correlation 5y | 76.9% |
CAGR 5y | 4.44% |
CAGR/Max DD 5y | 0.06 |
Sharpe Ratio 12m | 0.20 |
Alpha | -59.59 |
Beta | 1.023 |
Volatility | 49.88% |
Current Volume | 8890.5k |
Average Volume 20d | 984.9k |
As of April 02, 2025, the stock is trading at USD 32.23 with a total of 8,890,452 shares traded.
Over the past week, the price has changed by -48.85%, over one month by -48.29%, over three months by -53.87% and over the past year by -43.41%.
No, based on ValueRay Fundamental Analyses, Vaxcyte (NASDAQ:PCVX) is currently (April 2025) a stock to sell. It has a ValueRay Fundamental Rating of -54.57 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PCVX as of April 2025 is 30.23. This means that PCVX is currently overvalued and has a potential downside of -6.21%.
Vaxcyte has received a consensus analysts rating of 4.82. Therefor, it is recommend to buy PCVX.
- Strong Buy: 9
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, PCVX Vaxcyte will be worth about 33.8 in April 2026. The stock is currently trading at 32.23. This means that the stock has a potential upside of +4.78%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 150.2 | 366.1% |
Analysts Target Price | 149.9 | 365.1% |
ValueRay Target Price | 33.8 | 4.8% |